- Further refinement of if the i/Blue Imaging System will incorporate changes intended to meet critical verification requirements established through benchmark testing of competitive systems as well as feedback from preliminary meetings with the FDA
- Bladder cancer is anticipated to cause over 1,000,000 physician consultations per year, resulting in $4 billion in total costs for bladder cancer treatment and management
- Imagin Medical plans to complete its proprietary i/Blue Imaging System in 2022
The National Cancer Institute (“NCI”) lists urinary bladder cancer as the sixth most prevalent form of cancer in the United States. In 2021, NCI estimates that the total number of new bladder cancer cases will total 83,730, with deaths estimated at 17,200. The recurrence rate for bladder cancer is greater than 50%, making it one of the highest recurrence rates of all cancers. Approximately 724,000 people live in fear that their cancer will return (https://ibn.fm/BST5x).
Continuous monitoring of patients who might suffer a recurrence of bladder cancer will generate over 1,000,000 physician consultations per year. These visits add to the $4 billion in costs for bladder cancer management. It is estimated that 25% more tumors are removed using blue light cystoscopy (“BLC”), a more recent technology, that works in conjunction with white light, reducing recurrence and monitoring expenses over...
NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at http://ibn.fm/IMEXF
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text "STOCKS" to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.